Compare StocksAMD vs MRNA

Advanced Micro Devices, Inc. (AMD) vs Moderna, Inc. (MRNA): Which Is the Better Buy in 2026?

As of 2026-08-03, AMD is undervalued at $476, with a DCF intrinsic value of $357902777187 and a margin of safety of 100%. MRNA is fairly valued at $55, with an intrinsic value of $67 and a margin of safety of 18%. Of the two, AMD has the wider margin of safety.

AMD
Advanced Micro Devices, Inc.
$476.15
VS
MRNA
Moderna, Inc.
$54.82

Rewards

AMD
  • Free cash flow has grown at a 29.3% CAGR over the past 4 years, demonstrating strong earnings power growth.
  • Each dollar of retained earnings has created $2.01 of earning power — management is an exceptional capital allocator.
  • Management has timed buybacks well — 3 out of 4 years showed value-accretive repurchases.
MRNA

    Risks

    AMD
    • Altman Z-Score of 1.00 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
    • 7 insider sales totaling $144.5M with no purchases in the past 3 months — insiders are reducing their exposure.
    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -66.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.

    Key Valuation Metrics

    Learn more →
    AMD
    MRNA
    Valuation
    $7.17B
    Free Cash Flow
    $299.25M
    N/A
    FCF Yield
    1.38%
    158.72
    Trailing P/E
    N/A
    34.33
    Forward P/E
    -11.40
    Quality & Moat
    6.23%
    ROIC
    -122.02%
    8.06%
    ROE
    -39.00%
    53.06%
    Gross Margin
    -66.02%
    1.12
    PEG Ratio
    N/A
    Balance Sheet Safety
    Net cash
    Net Debt / Equity
    Net cash
    N/A
    Interest Coverage
    N/A
    -1.14
    Net Debt / EBITDA
    N/A
    0.00%
    Dividend Yield
    0.00%
    AMD: 4Ties: 1MRNA: 3
    AMDMRNA

    Historical Fundamentals

    Learn more →
    AMD

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    AMD
    $0.00
    created per $1 retained over 3 years
    Value Destroyer
    Σ Retained
    $6.83B
    Δ Market Cap
    +$149.39
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    AMD
    100.0% Margin of Safety
    Price is 100.0% below estimated fair value
    Current Price: $476.15
    Fair Value: $491923763775.66
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    MRNA
    18.2% Margin of Safety
    Price is 18.2% below estimated fair value
    Current Price: $54.82
    Fair Value: $66.99
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    AMD

    What growth rate is the market pricing in at $476?

    -30.0%
    Market-Implied Owner Earnings Growth
    Standard FCF implies -30.0%

    The market implies -30.0% Owner Earnings growth, below historical trends — potential opportunity.

    Standard FCF implies a more demanding -30.0%, reflecting heavy growth investment expected to generate future returns.

    MRNA

    What growth rate is the market pricing in at $55?

    +22.7%
    Market-Implied FCF Growth Rate

    Market pricing in significantly higher growth than history — aggressive.

    Economic Moat Score

    Learn more →
    AMD
    41/100
    Narrow Moat
    70+ Wide · 40-69 Narrow · <40 None

    Narrow moat with reinvestment efficiency as the key competitive advantage. Improving roic consistency would strengthen the moat.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    AMD
    -2.84
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    AMD
    Insiders 0.4%Institutions 72.0%Retail & Other 27.6%
    No. of Institutional Holders4,601
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    MRNA
    Insiders 7.3%Institutions 78.4%Retail & Other 14.3%
    No. of Institutional Holders1,066
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    AMD
    0
    Buys (3M)
    0
    Buys (12M)
    GUIDO PHILIP
    Officer
    $999,328
    @ $113.56 · 2025-05-20
    GUIDO PHILIP
    Officer
    $499,616
    @ $107.56 · 2025-02-07
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    AMD
    7
    Sells (3M)
    32
    Sells (12M)
    Total value (12M): $312.48M
    PAPERMASTER MARK D
    Chief Technology Officer
    $3.34M
    @ $556.43 · 2026-07-15
    PAPERMASTER MARK D
    Chief Technology Officer
    $3.22M
    @ $536.33 · 2026-06-15
    SU LISA T
    Chief Executive Officer
    $57.59M
    @ $460.69 · 2026-06-10
    DENZEL NORA M
    Director
    $5.45M
    @ $522.00 · 2026-06-02
    NORROD FORREST EUGENE
    Officer
    $8.41M
    @ $431.40 · 2026-05-20
    SU LISA T
    Chief Executive Officer
    $55.69M
    @ $445.51 · 2026-05-13
    GRASBY PAUL DARREN
    Officer
    $10.83M
    @ $444.39 · 2026-05-08
    PAPERMASTER MARK D
    Chief Technology Officer
    $10.96M
    @ $350.00 · 2026-04-24
    PAPERMASTER MARK D
    Chief Technology Officer
    $8.99M
    @ $271.47 · 2026-04-16
    PAPERMASTER MARK D
    Chief Technology Officer
    $740,925
    @ $225.00 · 2026-04-06
    SU LISA T
    Chief Executive Officer
    $16.90M
    @ $198.77 · 2026-03-12
    GRASBY PAUL DARREN
    Officer
    $1.54M
    @ $204.87 · 2026-03-11
    PAPERMASTER MARK D
    Chief Technology Officer
    $606,800
    @ $200.00 · 2026-03-04
    HAHN AVA M
    General Counsel
    $56,814
    @ $198.65 · 2026-02-18
    HU JEAN X
    Chief Financial Officer
    $4.02M
    @ $201.62 · 2026-02-17
    SU LISA T
    Chief Executive Officer
    $26.79M
    @ $214.36 · 2026-02-11
    NORROD FORREST EUGENE
    Officer
    $4.22M
    @ $216.81 · 2026-02-11
    HAHN AVA M
    General Counsel
    $572,454
    @ $234.42 · 2026-01-16
    SU LISA T
    Chief Executive Officer
    $26.89M
    @ $215.14 · 2025-12-11
    GRASBY PAUL DARREN
    Officer
    $2.19M
    @ $218.77 · 2025-12-04
    HU JEAN X
    Chief Financial Officer
    $3.05M
    @ $209.96 · 2025-11-24
    NORROD FORREST EUGENE
    Officer
    $4.46M
    @ $229.37 · 2025-11-19
    PAPERMASTER MARK D
    Chief Technology Officer
    $4.11M
    @ $240.12 · 2025-11-14
    PAPERMASTER MARK D
    Chief Technology Officer
    $3.77M
    @ $224.28 · 2025-10-15
    HAHN AVA M
    General Counsel
    $648,197
    @ $226.01 · 2025-10-06
    NORROD FORREST EUGENE
    Officer
    $371,272
    @ $165.01 · 2025-09-24
    PAPERMASTER MARK D
    Chief Technology Officer
    $2.67M
    @ $159.20 · 2025-09-15
    NORROD FORREST EUGENE
    Officer
    $2.77M
    @ $160.93 · 2025-09-10
    HAHN AVA M
    General Counsel
    $22,608
    @ $158.10 · 2025-09-02
    SU LISA T
    Chief Executive Officer
    $36.89M
    @ $163.97 · 2025-08-21
    PAPERMASTER MARK D
    Chief Technology Officer
    $2.99M
    @ $178.11 · 2025-08-15
    GRASBY PAUL DARREN
    Officer
    $1.73M
    @ $173.21 · 2025-08-12
    PAPERMASTER MARK D
    Chief Technology Officer
    $2.79M
    @ $155.03 · 2025-07-15
    PAPERMASTER MARK D
    Chief Technology Officer
    $2.03M
    @ $116.00 · 2025-06-13
    PAPERMASTER MARK D
    Chief Technology Officer
    $2.04M
    @ $116.59 · 2025-05-15
    PAPERMASTER MARK D
    Chief Technology Officer
    $1.67M
    @ $95.47 · 2025-04-15
    PAPERMASTER MARK D
    Chief Technology Officer
    $1.75M
    @ $100.27 · 2025-03-14
    PAPERMASTER MARK D
    Chief Technology Officer
    $1.99M
    @ $113.57 · 2025-02-14
    SU LISA T
    Chief Executive Officer
    $10.91M
    @ $142.66 · 2024-12-04
    SU LISA T
    Chief Executive Officer
    $10.91M
    @ $142.66 · 2024-12-04
    SU LISA T
    Chief Executive Officer
    $11.51M
    @ $143.87 · 2024-11-06
    NORROD FORREST EUGENE
    Officer
    $5.74M
    @ $141.67 · 2024-11-05
    SU LISA T
    Chief Executive Officer
    $11.58M
    @ $144.72 · 2024-09-11
    SU LISA T
    Chief Executive Officer
    $12.60M
    @ $157.44 · 2024-08-20
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    MRNA
    4
    Sells (3M)
    8
    Sells (12M)
    Total value (12M): $17.92M
    HOGE STEPHEN
    President
    $3.61M
    @ $67.60 · 2026-07-15
    HOGE STEPHEN
    President
    $2.74M
    @ $51.37 · 2026-06-15
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    KLINGER SHANNON THYME
    Officer
    $40,539
    @ $73.57 · 2024-09-09
    KLINGER SHANNON THYME
    Officer
    $8,777
    @ $76.99 · 2024-09-03
    HOGE STEPHEN
    President
    $24,483
    @ $76.99 · 2024-09-03
    KLINGER SHANNON THYME
    Officer
    $12,640
    @ $78.02 · 2024-08-29
    HOGE STEPHEN
    President
    $23,408
    @ $78.03 · 2024-08-29
    MOCK JAMES M
    Chief Financial Officer
    $12,640
    @ $78.02 · 2024-08-29
    KLINGER SHANNON THYME
    Officer
    $104,722
    @ $79.39 · 2024-08-28
    MOCK JAMES M
    Chief Financial Officer
    $104,881
    @ $79.40 · 2024-08-28
    HOGE STEPHEN
    President
    $21,363
    @ $84.11 · 2024-08-12
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    AMD
    FearGreed
    😐Neutral(49/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    MRNA
    FearGreed
    😨Fear(26/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    AMD
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (49)
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (26)
    View AMD Full AnalysisView MRNA Full Analysis

    Frequently Asked Questions: AMD vs MRNA

    Is Advanced Micro Devices, Inc. or Moderna, Inc. more undervalued in 2026?

    Based on our discounted cash flow model, AMD trades at a 100.0% margin of safety (intrinsic value $357902777187 vs. price $476), compared to MRNA's 18.2% margin of safety (intrinsic $67 vs. $55).

    Which stock has a wider economic moat, Advanced Micro Devices, Inc. or Moderna, Inc.?

    AMD scores 41/100 (Narrow moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Advanced Micro Devices, Inc. in financial distress?

    AMD's Altman Z-Score of 1.0 places it in the Distress zone, signaling elevated bankruptcy risk. MRNA scores 2.5 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which stock has higher return on invested capital, Advanced Micro Devices, Inc. or Moderna, Inc.?

    AMD earns 6.2% ROIC versus MRNA's -122.0%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.